CT 32228

• CAT Number: I025245
• CAS Number: 521064-34-6
• Molecular Formula: C16H13BrClN5
• Molecular Weight: 390.67
• Purity: 98%
• Synonyms: CT 32228; CT-32228; CT32228
• Solubility: Soluble in DMSO
• Appearance: Solid powder
• Storage: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
• IUPAC Name: 1,3,5-Triazine-2,4-diamine, N-(4-bromophenyl)-6-(5-chloro-2-methylphenyl)-
• InChI: InChI=1S/C16H13BrClN5/c1-9-2-5-11(18)8-13(9)14-21-15(19)23-16(22-14)20-12-6-3-10(17)4-7-12/h2-8H,1H3,(H3,19,20,21,22,23)
• InChIKey: NUPGPJBRKLLVNK-UHFFFAOYSA-N
• SMILES: NC1=NC(C2=CC(Cl)=CC=C2C)=NC(NC3=CC=C(Br)C=C3)=N1

CT 32228 (Cat No.: I025245) is a small-molecule inhibitor that targets HMG-CoA reductase, the key enzyme in the mevalonate pathway responsible for cholesterol biosynthesis. It functions similarly to statins by reducing intracellular cholesterol levels, making it valuable in cardiovascular and lipid metabolism research. CT 32228 has been studied for its effects on lipid regulation, atherosclerosis, and related metabolic disorders. Its specific structure and mechanism provide insights into alternative cholesterol-lowering strategies, and it serves as a research tool for understanding sterol regulatory pathways and drug development.

Reference

1: Douvas MG, Hogan KN, Ji Y, Hollenback D, Bonham L, Singer JW, Mitchell BS. Effect of lysophosphatidic acid acyltransferase-beta inhibition in acute leukemia. Leuk Res. 2006 Aug;30(8):1027-36. doi: 10.1016/j.leukres.2005.11.018. Epub 2006 Feb 20. PMID: 16488473.
2: Pagel JM, Laugen C, Bonham L, Hackman RC, Hockenbery DM, Bhatt R, Hollenback D, Carew H, Singer JW, Press OW. Induction of apoptosis using inhibitors of lysophosphatidic acid acyltransferase-beta and anti-CD20 monoclonal antibodies for treatment of human non-Hodgkin’s lymphomas. Clin Cancer Res. 2005 Jul 1;11(13):4857-66. doi: 10.1158/1078-0432.CCR-04-2352. PMID: 16000584.
3: Bonham L, Leung DW, White T, Hollenback D, Klein P, Tulinsky J, Coon M, de Vries P, Singer JW. Lysophosphatidic acid acyltransferase-beta: a novel target for induction of tumour cell apoptosis. Expert Opin Ther Targets. 2003 Oct;7(5):643-61. doi: 10.1517/14728222.7.5.643. PMID: 14498826.
4: Springett GM, Bonham L, Hummer A, Linkov I, Misra D, Ma C, Pezzoni G, Di Giovine S, Singer J, Kawasaki H, Spriggs D, Soslow R, Dupont J. Lysophosphatidic acid acyltransferase-beta is a prognostic marker and therapeutic target in gynecologic malignancies. Cancer Res. 2005 Oct 15;65(20):9415-25. doi: 10.1158/0008-5472.CAN-05-0516. Erratum in: Cancer Res. 2005 Dec 15;65(24):11785. PMID: 16230405.
5: La Rosée P, Jia T, Demehri S, Härtel N, de Vries P, Bonham L, Hollenback D, Singer JW, Melo JV, Druker BJ, Deininger MW. Antileukemic activity of lysophosphatidic acid acyltransferase-beta inhibitor CT32228 in chronic myelogenous leukemia sensitive and resistant to imatinib. Clin Cancer Res. 2006 Nov 1;12(21):6540-6. doi: 10.1158/1078-0432.CCR-06-0140. PMID: 17085669.